Start all patients on statins early after PCI

Adrian W. Messerli, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Herbert D. Aronow, MD, MPH
Department of Cardiovascular Medicine, The Cleveland Clinic

Dennis L. Sprecher, MD
Adjunct staff, The Cleveland Clinic; Director, Dyslipidemia, Discovery Medicine, GlaxoSmithKline; formerly head, Section of Cardiac Prevention, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Dennis Sprecher, MD, GlaxoSmithKline, 709 Swedelan Rd, UW2900, King of Prussia, PA 19406

Dr. Aronow has indicated that he serves as a consultant for and is on the speaker’s bureau of the Pfizer corporation.

Dr. Sprecher became employed by GlaxoSmithKline corporation after this paper was written and accepted.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Adrian W. Messerli, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Herbert D. Aronow, MD, MPH
Department of Cardiovascular Medicine, The Cleveland Clinic

Dennis L. Sprecher, MD
Adjunct staff, The Cleveland Clinic; Director, Dyslipidemia, Discovery Medicine, GlaxoSmithKline; formerly head, Section of Cardiac Prevention, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Dennis Sprecher, MD, GlaxoSmithKline, 709 Swedelan Rd, UW2900, King of Prussia, PA 19406

Dr. Aronow has indicated that he serves as a consultant for and is on the speaker’s bureau of the Pfizer corporation.

Dr. Sprecher became employed by GlaxoSmithKline corporation after this paper was written and accepted.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Adrian W. Messerli, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Herbert D. Aronow, MD, MPH
Department of Cardiovascular Medicine, The Cleveland Clinic

Dennis L. Sprecher, MD
Adjunct staff, The Cleveland Clinic; Director, Dyslipidemia, Discovery Medicine, GlaxoSmithKline; formerly head, Section of Cardiac Prevention, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Dennis Sprecher, MD, GlaxoSmithKline, 709 Swedelan Rd, UW2900, King of Prussia, PA 19406

Dr. Aronow has indicated that he serves as a consultant for and is on the speaker’s bureau of the Pfizer corporation.

Dr. Sprecher became employed by GlaxoSmithKline corporation after this paper was written and accepted.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.